S-095029 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how S-095029’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
S-095029 is under development for the treatment of solid tumors, metastatic gastric or colorectal cancers. It acts by targeting natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A). It is administered through intravenous infusion route.
Les Laboratoires Servier overview
Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others. The company also provides generic drugs and contract development and manufacturing services across its global network. It invests a substantial amount of revenue in R&D, particularly in France and Hungary. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, France
For a complete picture of S-095029’s drug-specific PTSR and LoA scores, buy the report here.